12 research outputs found
Ocular dynamics of <i>Garcinia cola</i> (Heckel) on healthy volunteers following bolus ingestion
Garcinia cola Heckel, an angiospermae belonging to the family Guttiferae, is known in commerce as bitter cola. It is a plant found
in the West African subregion, mostly in moist conditions, and often in association with Cola acuminata. The seeds are highly valued ingredients in African ethonomedicine. The seeds
have several social uses and applications in folk medicine. These seeds are ordinarily chewed by the local people without prescription or restriction. In an in vivo case control study, the effects of Garcinia cola on some visual functions: pupil diameter, near point of convergence (NPC), amplitude of accommodation (AA),
intraocular pressure (IOP), visual acuity (VA) and habitual phoria; following bolus ingestion of 20 g was undertaken using healthy visually active volunteers. Results showed that bolus ingestion of Garcinia cola constricted the pupil by 68%, reduced the NPC by 28%, increased the AA by 17.8% at peak effect and decreased
the intraocular pressure by 31% without affecting the distance and near VA. The lateral phoria at far and near tended towards esophoria. Possibly the miotic effect and reduction in IOP
could be of benefit to patients with raised IOP where conventional drugs may not be effective. Also it is possible that the effects on phoria could be exploited in oculomotor function in combination with visual training
The global threat of counterfeit drugs: Why industry and governments must communicate the dangers
Ocular effects of acute ingestion of Cola <i>nitida</i>(Linn) on healthy adult volunteers
Cola nitida Linn (Sterculiaceae) is an economic plant widely distributed throughout West Africa and possibly other parts of Africa.Members are malvalves because of their lobular nature. Because of its ubiquity, the plant plays an important role in commerce, and in social activities where it is casually eaten without prescription or restriction. The ethnopharmacological effects of bolus ingestion of 30g of Cola nitida was investigated on visually acute and healthy volunteers in order to determine its ocular implications or effects. Results showed that Cola nitida had no effecton the pupil diameter, visual acuity and intraocular pressure but improved the near point of convergence by 43% and increased the amplitude of accommodation by 11% while existing heterophorias are ameliorated. The stimulating effect of Cola nitida might overcome asthenopic symptoms with convergence insufficiency and allows near work to be donewithout stress. Somnolence and ocular muscle imbalance common features of the elderly canbe ameliorated or relieved
EUS-FNA with rescue FISH for the diagnosis of pancreatic carcinoma in patients with inconclusive on-site cytopathology.
Recommended from our members
Oral and extraoral plasmablastic lymphoma: Similarities and differences in clinicopathological characteristics
Oral and extraoral plasmablastic lymphoma: Similarities and differences in clinicopathological characteristics.
707PSAFETY AND EFFICACY OF NEOADJUVANT FOLFIRINOX IN PATIENTS (PTS) WITH LOCALLY ADVANCED PANCREATIC ADENOCARCINOMA (LAPC)
Abstract
Aim: In a retrospective study of 18 pts with unresectable (UR) or borderline resectable (BR) LAPC, neoadjuvant therapy with FOLFIRINOX with or without subsequent chemoradiation (CCRT) resulted in an R0 resection rate (RR) of 44% (Hosein et al, BMC Cancer 2012). The reported 1-year progression-free survival (PFS) was 83 % and the 1-year overall survival (OS) was 100 %. Toxicity profile was tolerable. In order to confirm these preliminary results, we analyzed a large cohort of pts treated in a similar fashion with mature follow-up.
Methods: Between 2008 and 2013, 51 treatment-naïve pts with LAPC were treated with first-line FOLFIRINOX with neoadjuvant intent. Pts were categorized as BR or UR using the NCCN criteria. Pts received FOLFIRINOX chemotherapy (at the full dose as described in the ACCORD-11 trial) until maximum response or tolerability, and then underwent surgery if their imaging suggested resectability. Pts then received CCRT if they were still UR or BR after FOLFIRINOX. The end points of this retrospective analysis were OS, PFS, R0 RR and toxicity profile.
Results: A total of 429 cycles were given with a median of 8 (range 2-29); 27 (53%) went on to receive CCRT. After a median follow-up of 17 mo (range 2-56), the Kaplan-Meier median OS was 35 mo (95% CI 26-45), the 3-yr OS rate was 42% and the median PFS was 14 mo (95% CI 11 – 16). By imaging criteria, 13 (26%) were converted to resectability and 10 (4 BR and 6 UR) of these had successful R0 resections. Pts who had R0 resections had a significantly longer survival than pts who did not (3-yr OS rate 67% vs 21%, log rank p = 0.042). Grade 1&2/3&4 chemotherapy-related toxicities were neutropenia (39%/20%), neutropenic fever (0%/12%), thrombocytopenia (53%/16%), anemia (63%/10%), fatigue (76%/6%), nausea (57%/4%) vomiting (22%/4%), neuropathy (53%/4%) and diarrhea (37%/10%).
Conclusions: FOLFIRINOX followed by chemoradiotherapy is feasible as neoadjuvant therapy in patients with unresectable LAPC. Although the resection rate was only 20%, the median OS of almost 3 years is appreciably longer than historical survival rates for this population. Prospective controlled trials testing this algorithm in LAPC are ongoing.
Disclosure: All authors have declared no conflicts of interest